Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus.

Purdy JB, Gafni RI, Reynolds JC, Zeichner S, Hazra R.

J Pediatr. 2008 Apr;152(4):582-4. doi: 10.1016/j.jpeds.2007.12.020.

2.

Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children.

Gafni RI, Hazra R, Reynolds JC, Maldarelli F, Tullio AN, DeCarlo E, Worrell CJ, Flaherty JF, Yale K, Kearney BP, Zeichner SL.

Pediatrics. 2006 Sep;118(3):e711-8. Epub 2006 Aug 21.

PMID:
16923923
3.

Long-term efficacy and safety of tenofovir disoproxil fumarate in HIV-1-infected adolescents failing antiretroviral therapy: the final results of study GS-US-104-0321.

Della Negra M, De Carvalho AP, De Aquino MZ, Pinto JA, Da Silva MT, Andreatta KN, Graham B, Liu YP, Quirk EK.

Pediatr Infect Dis J. 2015 Apr;34(4):398-405. doi: 10.1097/INF.0000000000000649.

PMID:
25599284
4.

Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection.

Hazra R, Gafni RI, Maldarelli F, Balis FM, Tullio AN, DeCarlo E, Worrell CJ, Steinberg SM, Flaherty J, Yale K, Kearney BP, Zeichner SL.

Pediatrics. 2005 Dec;116(6):e846-54. Epub 2005 Nov 15.

PMID:
16291735
5.

Impact of switching from zidovudine to tenofovir disoproxil fumarate on bone mineral density and markers of bone metabolism in virologically suppressed HIV-1 infected patients; a substudy of the PREPARE study.

Cotter AG, Vrouenraets SM, Brady JJ, Wit FW, Fux CA, Furrer H, Brinkman K, Sabin CA, Reiss P, Mallon PW; PREPARE (Preventing Progression of Adipose Tissue Redistribution) Investigators.

J Clin Endocrinol Metab. 2013 Apr;98(4):1659-66. doi: 10.1210/jc.2012-3686. Epub 2013 Feb 22.

PMID:
23436922
6.

Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco.

Liu AY, Vittinghoff E, Sellmeyer DE, Irvin R, Mulligan K, Mayer K, Thompson M, Grant R, Pathak S, O'Hara B, Gvetadze R, Chillag K, Grohskopf L, Buchbinder SP.

PLoS One. 2011;6(8):e23688. doi: 10.1371/journal.pone.0023688. Epub 2011 Aug 29.

7.

Tenofovir disoproxil fumarate and bone mineral density: a 60-month longitudinal study in a cohort of HIV-infected youths.

Viganò A, Zuccotti GV, Puzzovio M, Pivetti V, Zamproni I, Cerini C, Fabiano V, Giacomet V, Mora S.

Antivir Ther. 2010;15(7):1053-8. doi: 10.3851/IMP1650.

PMID:
21041922
8.

A 12-month treatment with tenofovir does not impair bone mineral accrual in HIV-infected children.

Giacomet V, Mora S, Martelli L, Merlo M, Sciannamblo M, Viganò A.

J Acquir Immune Defic Syndr. 2005 Dec 1;40(4):448-50.

PMID:
16280700
9.

Efficacy, safety and pharmacokinetics of tenofovir disoproxil fumarate in virologic-suppressed HIV-infected children using weight-band dosing.

Aurpibul L, Cressey TR, Sricharoenchai S, Wittawatmongkol O, Sirisanthana V, Phongsamart W, Sudjaritruk T, Chokephaibulkit K.

Pediatr Infect Dis J. 2015 Apr;34(4):392-7. doi: 10.1097/INF.0000000000000633. Erratum in: Pediatr Infect Dis J. 2015 Aug;34(8):847.

PMID:
25760566
10.

Bone turnover, osteoprotegerin/RANKL and inflammation with antiretroviral initiation: tenofovir versus non-tenofovir regimens.

Brown TT, Ross AC, Storer N, Labbato D, McComsey GA.

Antivir Ther. 2011;16(7):1063-72. doi: 10.3851/IMP1874.

11.

96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study.

Moyle GJ, Stellbrink HJ, Compston J, Orkin C, Arribas JR, Domingo P, Granier C, Pearce H, Sedani S, Gartland M; ASSERT Team.

Antivir Ther. 2013;18(7):905-13. doi: 10.3851/IMP2667. Epub 2013 Jul 31.

PMID:
23899468
12.

Longitudinal study on mitochondrial effects of didanosine-tenofovir combination.

López S, Negredo E, Garrabou G, Puig J, Ruiz L, Sanjurjo E, Ramos X, Infante AB, Casademont J, Cardellach F, Clotet B, Miró O.

AIDS Res Hum Retroviruses. 2006 Jan;22(1):33-9.

PMID:
16438643
13.

Emtricitabine/tenofovir disoproxil fumarate: a review of its use in HIV-1 pre-exposure prophylaxis.

Plosker GL.

Drugs. 2013 Mar;73(3):279-91. doi: 10.1007/s40265-013-0024-4. Review.

PMID:
23444256
14.

Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor-Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study.

Mills A, Crofoot G Jr, McDonald C, Shalit P, Flamm JA, Gathe J Jr, Scribner A, Shamblaw D, Saag M, Cao H, Martin H, Das M, Thomas A, Liu HC, Yan M, Callebaut C, Custodio J, Cheng A, McCallister S.

J Acquir Immune Defic Syndr. 2015 Aug 1;69(4):439-45. doi: 10.1097/QAI.0000000000000618.

PMID:
25867913
15.

Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus.

Ray AS, Fordyce MW, Hitchcock MJ.

Antiviral Res. 2016 Jan;125:63-70. doi: 10.1016/j.antiviral.2015.11.009. Epub 2015 Nov 27. Review.

16.

A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206.

Tungsiripat M, Kitch D, Glesby MJ, Gupta SK, Mellors JW, Moran L, Jones L, Alston-Smith B, Rooney JF, Aberg JA.

AIDS. 2010 Jul 17;24(11):1781-4. doi: 10.1097/QAD.0b013e32833ad8b4.

17.

Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naïve subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934.

Margot NA, Enejosa J, Cheng AK, Miller MD, McColl DJ; Study 934 Team.

J Acquir Immune Defic Syndr. 2009 Oct 1;52(2):209-21. doi: 10.1097/QAI.0b013e3181b05f7c.

PMID:
19644384
18.

Experience with tenofovir disoproxil fumarate for antiretroviral therapy.

Stephan C.

Expert Opin Pharmacother. 2008 May;9(7):1197-209. doi: 10.1517/14656566.9.7.1197. Review.

PMID:
18422476
19.

Effect of baseline renal function on tenofovir-containing antiretroviral therapy outcomes in Zambia.

Mulenga L, Musonda P, Mwango A, Vinikoor MJ, Davies MA, Mweemba A, Calmy A, Stringer JS, Keiser O, Chi BH, Wandeler G; IeDEA-Southern Africa.

Clin Infect Dis. 2014 May;58(10):1473-80. doi: 10.1093/cid/ciu117. Epub 2014 Feb 27.

20.

Reduced quantitative ultrasound bone mineral density in HIV-infected patients on antiretroviral therapy in Senegal.

Cournil A, Eymard-Duvernay S, Diouf A, Moquet C, Coutherut J, Ngom Gueye NF, Cames C, Taverne B, Bork K, Sow PS, Delaporte E; ANRS 1215 Study Group.

PLoS One. 2012;7(2):e31726. doi: 10.1371/journal.pone.0031726. Epub 2012 Feb 16.

Supplemental Content

Support Center